Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 site in 1 country899 target enrollmentJune 2008

ConditionsHypertension

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Hypertension
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Enrollment: 899
Locations: 1
Primary Endpoint: Description of hypertensive patients in terms of presence of associated cardiovascular (CV) risk factors (number of additional CV risk factors and frequency)
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To assess the pattern of hypertension in the population in terms of presence of additional risk factors (ARF) and cardiovascular risk stratification.

Detailed Description

routine physician visits

Registry

clinicaltrials.gov

Start Date

June 2008

End Date

February 2009

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age 18 to 80 years old
•Patients with hypertension: newly diagnosed and /or already diagnosed and treated , whether at goal or not for the blood pressure level;
•Patients with no history of CHD/CVD

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Description of hypertensive patients in terms of presence of associated cardiovascular (CV) risk factors (number of additional CV risk factors and frequency)

Secondary Outcomes

Description of pattern of management of HT and CVD prevention, through lifestyle and use of drug therapies,
Estimate adherence to treatment using the Morisky Adherence Scale (MAS)
Estimation of hypertensive patients CV risk stratification based on ESH/ESC Hypertension Guidelines 2007 and to compare it with physicians' estimation of CV risk.